View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 9, 2019updated 13 Aug 2019 4:56am

Arrowhead initiates Phase II/III trial of RNAi therapeutic ARO-AAT

Arrowhead Pharmaceuticals has initiated a potentially pivotal Phase II/III clinical trial of ARO-AAT, its second generation subcutaneously administered RNA interference (RNAi) therapeutic.

Arrowhead Pharmaceuticals has initiated a potentially pivotal Phase II/III clinical trial of ARO-AAT, its second generation subcutaneously administered RNA interference (RNAi) therapeutic.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

As part of the initiation, the company dosed the first patient in the SEQUOIA (AROAAT2001) trial.

Arrowhead is developing the RNAi therapeutic as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).

Arrowhead Pharmaceuticals chief operating officer and R&D head Bruce Given said: “ARO-AAT is the first RNAi therapeutic derived from our proprietary Targeted RNAi Molecule, or TRiM, platform to reach a potentially pivotal study.

“This is a significant milestone for Arrowhead and, more importantly, it represents potential hope for patients living with alpha-1 liver disease, who currently have no available treatment options other than liver transplant.”

The placebo-controlled, adaptive design Phase II/III SEQUOIA (NCT03945292) trial will evaluate the safety, efficacy, and tolerability of the drug candidate ARO-AAT administered subcutaneously to patients with AATD associated liver disease.

A total of 120 patients will be given at least nine doses, or approximately two years worth of treatment, with ARO-AAT or placebo.

Doses will then be administered on day one, 29, and roughly every 12 weeks.

Part A of the study will be four-arm and placebo-controlled and will feed seamlessly into a two-arm placebo-controlled Part B component.

The primary objective for Part A is to select a single dose level for use in Part B of the study, while the primary objective for Part B is to evaluate the efficacy of ARO-AAT.

In September last year, Arrowhead completed dosing patients in a Phase I clinical trial (AROAAT1001) of ARO-AAT for the treatment of a liver disease caused by AATD.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena